Feasibility of detecting atrophy relevant for disability and cognition in multiple sclerosis using 3D-FLAIR von Noteboom, Samantha, van Nederpelt, D. R., Bajrami, A., Moraal, B., Caan, M. W. A., Barkhof, F., Calabrese, M., Vrenken, H., Strijbis, E. M. M., Steenwijk, M. D., Schoonheim, M. M.

Volltext

Neurophysiological brain function predicts response to cognitive rehabilitation and mindfulness in multiple sclerosis: a randomized trial von Nauta, Ilse M., Kessels, Roy P. C., Bertens, Dirk, Stam, Cornelis J., Strijbis, Eva E. M., Hillebrand, Arjan, Fasotti, Luciano, Uitdehaag, Bernard M. J., Hulst, Hanneke E., Speckens, Anne E. M., Schoonheim, Menno M., de Jong, Brigit A.

Volltext

Influence of personalized extended interval dosing on the natalizumab wearing-off effect - a sub-study of the NEXT-MS trial von Toorop, A.A., Wessels, M.H.J., Gelissen, L.M.Y., Hoitsma, E., Zeinstra, E.M.P.E., van Rooij, L.C., van Munster, C.E.P., Vennegoor, A., Mostert, J.P., Wokke, B.H.A., Kalkers, N.F., Hoogervorst, E.L.J., van Eijk, J.J.J., Roosendaal, C.M., Kragt, J.J., Eurelings, M., van Genugten, J., Nielsen, J., Sinnige, L.G.F., Kloosterziel, M.E., Arnoldus, E.P.J., van Dijk, G.W., Bouvy, W.H., Strijbis, E.M.M., van Oosten, B.W., de Jong, B.A., Lissenberg-Witte, B.I., Rispens, T., Uitdehaag, B.M.J., Killestein, J., van Kempen, Z.L.E.

Volltext

Discontinuation of first-line disease-modifying therapy in relapse onset multiple sclerosis von Coerver, E.M.E., Bourass, A., Wessels, M.H.J., van Kempen, Z.L.E., Jasperse, M.M.S., Tonino, B.A.R., Barkhof, F., Mostert, J., Uitdehaag, B.M.J., Killestein, J., Strijbis, E.M.M.

Volltext

Long-term neuroprotective effects of natalizumab and fingolimod in multiple sclerosis: Evidence from real-world clinical data von Noteboom, S., Strijbis, E.M.M., Coerver, E.M.E., Colato, E., van Kempen, Z.L.E., Jasperse, B., Vrenken, H., Killestein, J., Schoonheim, M.M., Steenwijk, M.D.

Volltext

White Matter Diffusion Changes during the First Year of Natalizumab Treatment in Relapsing-Remitting Multiple Sclerosis von Wiebenga, O T, Schoonheim, M M, Hulst, H E, Nagtegaal, G J A, Strijbis, E M M, Steenwijk, M D, Polman, C H, Pouwels, P J W, Barkhof, F, Geurts, J J G

Volltext

Longitudinal humoral response after SARS-CoV-2 vaccination in ocrelizumab treated MS patients: To wait and repopulate? von van Kempen, Z.L.E., Wieske, L., Stalman, E.W., Kummer, L. Y. L, van Dam, P.J., Volkers, A.G., Boekel, L., Toorop, A.A., Strijbis, E.M.M., Tas, S.W., Wolbink, G.J., Löwenberg, M., van Sandt, C., ten Brinke, A., Verstegen, N.J.M., Steenhuis, M., Kuijpers, T.W., van Ham, S.M., Rispens, T., Eftimov, F., Killestein, J.

Volltext

Cross-sectional and longitudinal correlations between the Arm Function in Multiple Sclerosis Questionnaire (AMSQ) and other outcome measures in multiple sclerosis von Molenaar, P.C.G., Strijbis, E.M.M., van Munster, C.E.P., Uitdehaag, B.M.J., Kalkers, N.F.

Volltext

Impaired saccadic eye movements in multiple sclerosis are related to altered functional connectivity of the oculomotor brain network von Nij Bijvank, J.A., Strijbis, E.M.M., Nauta, I.M., Kulik, S.D., Balk, L.J., Stam, C.J., Hillebrand, A., Geurts, J.J.G., Uitdehaag, B.M.J., van Rijn, L.J., Petzold, A., Schoonheim, M.M.

Volltext

The use of multi-domain patient reported outcome measures for detecting clinical disease progression in multiple sclerosis von van ‘t Hullenaar, C.A.A., Coerver, E., Kalkers, N.F., van Kempen, Z., Koch, M., Uitdehaag, B.M.J., Killestein, J., Strijbis, E.M.M.

Volltext

Natalizumab discontinuation in a Dutch real-world cohort von Coerver, E.M.E., Wessels, M.H.J., van Lierop, Z.Y.G., van Kempen, Z.L.E., Killestein, J., Strijbis, E.M.M.

Volltext

Quality of life should be the primary outcome for disease modifying therapy trials in MS—No von Strijbis, EMM, Koch, MW, de Jong, BA

Volltext

Mild progressive multifocal leukoencephalopathy after switching from natalizumab to ocrelizumab von Toorop, Alyssa A., van Lierop, Zoë Y.G., Strijbis, Eva E.M., Teunissen, Charlotte E., Petzold, Axel, Wattjes, Mike P., Barkhof, Frederik, de Jong, Brigit A., van Kempen, Zoé L.E., Killestein, Joep

Volltext

The wearing-off phenomenon of ocrelizumab in patients with multiple sclerosis von Toorop, A.A., van Lierop, Z.Y.G.J., Strijbis, E.M.M., Teunissen, C.E., Barkhof, F., Uitdehaag, B.M.J., van Kempen, Z.L.E., Killestein, J.

Volltext

Ocrelizumab after natalizumab in JC-virus positive relapsing remitting multiple sclerosis patients von van Lierop, ZYGJ, Toorop, AA, Coerver, EME, Willemse, EAJ, Strijbis, EMM, Kalkers, NF, Moraal, B, Barkhof, F, Teunissen, CE, Killestein, J, van Kempen, ZLE

Volltext

SARS-CoV-2 Antibodies in Adult Patients With Multiple Sclerosis in the Amsterdam MS Cohort von van Kempen, Zoé L. E, Strijbis, Eva M. M, Al, Marissa M. C. T, Steenhuis, Maurice, Uitdehaag, Bernard M. J, Rispens, Theo, Killestein, Joep

Volltext

The role of CD56bright NK cells in neurodegenerative disorders von Rodriguez-Mogeda, Carla, van Ansenwoude, Chaja M. J, van der Molen, Lennart, Strijbis, Eva M. M, Mebius, Reina E, de Vries, Helga E

Volltext

Adipokines in multiple sclerosis patients are related to clinical and radiological measures von Loonstra, Floor C., Falize, Kim F., de Ruiter, Lodewijk R. J., Schoonheim, Menno M., Strijbis, Eva M. M., Killestein, Joep, de Vries, Helga E., Uitdehaag, Bernard M. J., Rijnsburger, Merel

Volltext

Artificial double inversion recovery images for (juxta)cortical lesion visualization in multiple sclerosis von Bouman, Piet M, Strijbis, Victor IJ, Jonkman, Laura E, Hulst, Hanneke E, Geurts, Jeroen JG, Steenwijk, Martijn D

Volltext

Personalized B-cell tailored dosing of ocrelizumab in patients with multiple sclerosis during the COVID-19 pandemic von van Lierop, Zoë YGJ, Toorop, Alyssa A, van Ballegoij, Wouter JC, Olde Dubbelink, Tom BG, Strijbis, Eva MM, de Jong, Brigit A, van Oosten, Bob W, Moraal, Bastiaan, Teunissen, Charlotte E, Uitdehaag, Bernard MJ, Killestein, Joep, Kempen, Zoé LE van

Volltext